In brief
In a significant legal ruling, U.S. District Judge Rita Lin has ordered the Trump administration to restore $500 million in federal grant funding that was suspended at UCLA. The judge found that the government's actions likely violated federal law regarding funding cuts. The decision follows UCLA's earlier announcement that the administration had halted $584 million in federal grants, raising concerns over potential civil rights violations related to antisemitism and affirmative action policies. This ruling marks a pivotal moment in preserving research funding crucial for various medical studies at UCLA.
LOS ANGELES (AP) - A federal judge has ordered the Trump administration to reinstate $500 million in federal grant funding that was frozen at the University of California, Los Angeles (UCLA). U.S. District Judge Rita Lin granted a preliminary injunction on Monday, indicating that the government's actions likely violated the Administrative Procedure Act, which entails specific protocols for federal funding adjustments.
In August, UCLA publicly declared that the administration had suspended $584 million in federal grants, citing potential civil rights violations concerning antisemitism and affirmative action within the institution. Judge Lin's ruling reinstates some funding lost earlier, including $81 million from the National Science Foundation, which had previously been cut under similar circumstances.
The case underscores broader tensions involving the Trump administration's influence over educational institutions, as community concerns grow regarding the implications of federal funding control. The White House has yet to respond to requests for comments on Monday’s ruling.
California Governor Gavin Newsom has criticized the administration's previous proposals for settling investigations at UCLA as attempts at extortion, noting that such actions could devastate the university's financial structure.
Recent discussions reveal that the halted federal grants are tied to important medical research endeavors at UCLA, including studies critical to understanding and addressing diseases like Parkinson's and cancer. This ruling, therefore, is not just a legal victory but is projected to have cascading impacts on ongoing health research and institutional integrity.
